Wordt geladen...
Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8(+) T cell immune response and antitumor effects in a preclinical cervical cancer model
BACKGROUND: Bortezomib, a proteasome inhibitor and suberoylanilide hydroxamic acid (SAHA, also known as Vorinostat), a histone deacetylase inhibitor, have been recognized as potent chemotherapeutic drugs. Bortezomib and SAHA are FDA-approved for the treatment of cutaneous T cell lymphoma and multipl...
Bewaard in:
| Gepubliceerd in: | J Biomed Sci |
|---|---|
| Hoofdauteurs: | , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4298946/ https://ncbi.nlm.nih.gov/pubmed/25591912 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12929-014-0111-1 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|